The INFORM real-world evidence study shows impact of semaglutide on reducing ‘food noise’, and the STEP UP clinical trial highlights semaglutide’s effect on control of eating and body composition ...

Even though weight loss drugs like Ozempic and Wegovy are medical breakthroughs, scientists are continuing to work on the ...

A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names Ozempic (pre-filled pen) and ...

The future of obesity therapeutics is being written now – be a part of it! Visit the full agenda and speakers here: ...

Eli Lilly & Company LLY and Pfizer PFE are both large-cap U.S. pharmaceutical giants with diversified drug portfolios and ...

The 7 major Obesity Market is expected tp reach USD 76.6 Million by 2035, exhibiting a CAGR of 14.62% during 2025-2035. BROOKLYN, NY, UNITED STATES, August 25, 2025 /EINPresswire.com/ -- The 7 major ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance ...

Novo Nordisk (NVO) says its novel obesity drug, amycretin, shows promising results with up to 24% of weight loss in a Phase 1/2 trial. Read more here.